JP2024515086A - 敗血症の早期検出のためのｇｄｆ１５マーカーパネル - Google Patents

敗血症の早期検出のためのｇｄｆ１５マーカーパネル Download PDF

Info

Publication number
JP2024515086A
JP2024515086A JP2023563986A JP2023563986A JP2024515086A JP 2024515086 A JP2024515086 A JP 2024515086A JP 2023563986 A JP2023563986 A JP 2023563986A JP 2023563986 A JP2023563986 A JP 2023563986A JP 2024515086 A JP2024515086 A JP 2024515086A
Authority
JP
Japan
Prior art keywords
biomarker
subject
amount
bilirubin
strem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023563986A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515086A5 (https=
Inventor
グリューネバルト，フェリックス
イェーガー，ヴィクトル・ヨハン・ラウル
クラマー，マルティン
シュッツ，フィリップ
ホルタイ，マリア フォン
ヴェーバー，シュテフェン
ベクマイヤー，ハイケ
ビーンヒューズ－テレン，ウルスラ－ヘンリケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2024515086A publication Critical patent/JP2024515086A/ja
Publication of JP2024515086A5 publication Critical patent/JP2024515086A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2023563986A 2021-04-30 2022-04-29 敗血症の早期検出のためのｇｄｆ１５マーカーパネル Pending JP2024515086A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21171497 2021-04-30
EP21171497.7 2021-04-30
PCT/EP2022/061543 WO2022229415A2 (en) 2021-04-30 2022-04-29 Gdf15 marker panels for early detection of sepsis

Publications (2)

Publication Number Publication Date
JP2024515086A true JP2024515086A (ja) 2024-04-04
JP2024515086A5 JP2024515086A5 (https=) 2025-05-08

Family

ID=75746439

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023563986A Pending JP2024515086A (ja) 2021-04-30 2022-04-29 敗血症の早期検出のためのｇｄｆ１５マーカーパネル

Country Status (5)

Country Link
US (1) US20240230673A1 (https=)
EP (1) EP4330684A2 (https=)
JP (1) JP2024515086A (https=)
CN (1) CN117203528A (https=)
WO (1) WO2022229415A2 (https=)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519916A (ja) * 2004-01-27 2007-07-19 ビオエクセル ソシエタ ペル アチオニ サンプル中の可溶性のｔｒｅｍ−１レベルを測定することによって伝染病を診断する方法
JP2009501521A (ja) * 2005-07-13 2009-01-22 ベス イスラエル ディーコネス メディカル センター 炎症応答を診断および処置する方法
EP2490027A1 (en) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Means and methods for diagnosing pregnancy complications based on GDF-15 and PlGF/sFlt1
JP2013527453A (ja) * 2010-05-17 2013-06-27 エフ．ホフマン−ラ ロシュ アーゲー 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法
JP2014505259A (ja) * 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
JP2002543841A (ja) 1999-05-17 2002-12-24 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー ＴＧＦ−βスーパーファミリーの新規のメンバーであるＧＤＦ―１５の神経保護特性
CA2476597C (en) 2002-02-28 2011-05-17 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analysing mixtures of substances
WO2005113585A2 (en) 2004-05-20 2005-12-01 Acceleron Pharma Inc. Modified tgf-beta superfamily polypeptides
CN103123359B (zh) 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
JP5722587B2 (ja) 2009-10-13 2015-05-20 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性脳卒中または一過性脳虚血発作を有する患者における細菌感染の診断のためのプロカルシトニン及び抗生物質治療のガイダンス
RU2016112915A (ru) 2013-09-05 2017-10-09 Эф-Ай-Оу Корпорейшн Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007519916A (ja) * 2004-01-27 2007-07-19 ビオエクセル ソシエタ ペル アチオニ サンプル中の可溶性のｔｒｅｍ−１レベルを測定することによって伝染病を診断する方法
JP2009501521A (ja) * 2005-07-13 2009-01-22 ベス イスラエル ディーコネス メディカル センター 炎症応答を診断および処置する方法
JP2013527453A (ja) * 2010-05-17 2013-06-27 エフ．ホフマン−ラ ロシュ アーゲー 急性炎症における生存および回復を推定するためのｇｄｆ−１５に基づく手段および方法
JP2014505259A (ja) * 2011-02-03 2014-02-27 アボット・ラボラトリーズ 慢性心不全における予後診断および診断の方法
EP2490027A1 (en) * 2011-02-15 2012-08-22 Roche Diagnostics GmbH Means and methods for diagnosing pregnancy complications based on GDF-15 and PlGF/sFlt1

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN NIEDERWANGER ET AL.: ""Antithrombin deficiency is associated with mortality and impaired organ function in septic pediatr", PEERJ, vol. 6, JPN6026013047, 5 September 2018 (2018-09-05), pages 5538, ISSN: 0005831076 *
ERIC AP STEEGERS ET AL.: ""Pre-eclampsia"", THE LANCET, vol. 376, no. 9741, JPN6026013050, August 2010 (2010-08-01), pages 631 - 644, ISSN: 0005831078 *
JULIO A. CHIRINOS ET AL.: ""Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ej", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 75, no. 11, JPN6026013051, March 2020 (2020-03-01), pages 1281 - 1295, ISSN: 0005831079 *
LI M ET AL.: ""Study on the value of mitochondrial associated protein fumarylacetoacetate domain containing prote", ZHONGHUA WEI ZHONG BING JI JIU YI XUE, vol. 33, no. 2, JPN6026013041, 28 February 2021 (2021-02-28), pages 180 - 185, ISSN: 0005831074 *
LUKAS BUENDGENS ET AL.: ""Growth Differentiation Factor-15 Is a Predictor of Mortality in Critically Ill Patients with Sepsi", DISEASE MARKERS, vol. 2017, JPN6026013049, 2017, pages 1 - 10, ISSN: 0005831077 *
SIMON SKIBSTED ET AL.: ""Biomarkers of Endothelial Cell Activation in Early Sepsis"", SHOCK, vol. 39, no. 5, JPN6026013045, May 2013 (2013-05-01), pages 427 - 432, ISSN: 0005831075 *
TESS CRUICKSHANK ET AL.: ""Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implic", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 10, no. 16, JPN6026013052, 17 August 2021 (2021-08-17), ISSN: 0005831080 *

Also Published As

Publication number Publication date
WO2022229415A3 (en) 2022-12-22
WO2022229415A2 (en) 2022-11-03
CN117203528A (zh) 2023-12-08
US20240230673A1 (en) 2024-07-11
EP4330684A2 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
JP2026048754A (ja) 敗血症の早期検出用のｐｃｔマーカーパネル
JP2024516678A (ja) 敗血症の早期検出用のｓｔｒｅｍ１マーカーパネル
JP2024516680A (ja) 敗血症の早期検出用のｉｌ６マーカーパネル
JP2024516677A (ja) 敗血症の早期検出用のｎｇａｌマーカーパネル
JP2024515086A (ja) 敗血症の早期検出のためのｇｄｆ１５マーカーパネル
JP2024516679A (ja) 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル
JP2024516001A (ja) 敗血症の早期検出のためのｅｓｍ１マーカーパネル
JP2024516681A (ja) 敗血症の早期検出のためのｓＦｌｔ１マーカーパネル
US20240230672A1 (en) Presepsin marker panels for early detection of sepsis
JP2024537774A (ja) 敗血症の早期検出のためのＭＲ－ｐｒｏＡＤＭマーカーパネル
WO2023156655A1 (en) Dll1 marker panels for early detection of sepsis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260401